The current state of hormonal therapy for prostate cancer - PubMed (original) (raw)
Review
. 2002 May-Jun;52(3):154-79.
doi: 10.3322/canjclin.52.3.154.
Affiliations
- PMID: 12018929
- DOI: 10.3322/canjclin.52.3.154
Free article
Review
The current state of hormonal therapy for prostate cancer
Beth A Hellerstedt et al. CA Cancer J Clin. 2002 May-Jun.
Free article
Abstract
Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated. Prevention of the side effects of therapy has led to the development of alternative schedules and therapeutics.
Summary for patients in
- Patient page. Early detection of prostate cancer.
[No authors listed] [No authors listed] CA Cancer J Clin. 2002 May-Jun;52(3):180. doi: 10.3322/canjclin.52.3.180. CA Cancer J Clin. 2002. PMID: 12018930 No abstract available.
Similar articles
- Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
Bollack C, Rougeron G. Bollack C, et al. Am J Clin Oncol. 1988;11 Suppl 2:S156-9. doi: 10.1097/00000421-198801102-00037. Am J Clin Oncol. 1988. PMID: 2977270 - Hormonal management of advanced adenocarcinoma of the prostate.
Miles BJ. Miles BJ. Henry Ford Hosp Med J. 1989;37(1):16-8. Henry Ford Hosp Med J. 1989. PMID: 2670839 No abstract available. - Endocrine treatment of prostate cancer.
Tammela T. Tammela T. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review. - [Significance of neoadjuvant therapy for prostate cancer].
Okada K, Hachiya T. Okada K, et al. Nihon Hinyokika Gakkai Zasshi. 1997 Sep;88(9):769-77. doi: 10.5980/jpnjurol1989.88.769. Nihon Hinyokika Gakkai Zasshi. 1997. PMID: 9364842 Review. Japanese. No abstract available. - Initiation of LHRH monotherapy for prostate cancer.
Milsted RA. Milsted RA. Prog Clin Biol Res. 1989;303:69-74. Prog Clin Biol Res. 1989. PMID: 2528742 Review. No abstract available.
Cited by
- Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.
Dias Silva É, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, de Souza AA, Laranjo A Jr, Clark O, Magna LA, Castilho LN, Reis LO. Dias Silva É, et al. Int Urol Nephrol. 2012 Aug;44(4):1039-44. doi: 10.1007/s11255-012-0134-z. Int Urol Nephrol. 2012. PMID: 22315155 Clinical Trial. - Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine.
Marshall DJ, San Mateo LR, Rudnick KA, McCarthy SG, Harris MC, McCauley C, Schantz A, Geng D, Cawood P, Snyder LA. Marshall DJ, et al. Cancer Immunol Immunother. 2005 Nov;54(11):1082-94. doi: 10.1007/s00262-005-0687-0. Epub 2005 Jul 27. Cancer Immunol Immunother. 2005. PMID: 16047142 Free PMC article. - Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.
Wu C, Chen W, Wu J, Zhang X, Huang X, Lin R, Zhu B, Jiang H. Wu C, et al. Clin Exp Metastasis. 2019 Jun;36(3):199-209. doi: 10.1007/s10585-019-09963-4. Epub 2019 Apr 8. Clin Exp Metastasis. 2019. PMID: 30963355 Review. - Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ, Milowsky MI, Whang YE. Crona DJ, et al. Clin Pharmacol Ther. 2015 Dec;98(6):582-9. doi: 10.1002/cpt.256. Epub 2015 Oct 1. Clin Pharmacol Ther. 2015. PMID: 26331358 Free PMC article. Review. - Shikonin enhances the antitumor effect of cabazitaxel in prostate cancer stem cells and reverses cabazitaxel resistance by inhibiting ABCG2 and ALDH3A1.
Wang L, Stadlbauer B, Lyu C, Buchner A, Pohla H. Wang L, et al. Am J Cancer Res. 2020 Nov 1;10(11):3784-3800. eCollection 2020. Am J Cancer Res. 2020. PMID: 33294267 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical